• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

D-手性肌醇(DCI)对肥胖型多囊卵巢综合征患者促黄体生成素(LH)和胰岛素分泌的调节作用。

Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.

作者信息

Genazzani Alessandro D, Santagni Susanna, Rattighieri Erika, Chierchia Elisa, Despini Giulia, Marini Giulia, Prati Alessia, Simoncini Tommaso

机构信息

Department of Obstetrics and Gynecology, Gynecological Endocrinology Centre, University of Modena and Reggio Emilia , Modena , Italy.

出版信息

Gynecol Endocrinol. 2014 Jun;30(6):438-43. doi: 10.3109/09513590.2014.897321. Epub 2014 Mar 7.

DOI:10.3109/09513590.2014.897321
PMID:24601829
Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine condition that affects fertility through oligo-ovulation, hyperandrogenism and polycystic morphology of the ovaries. Since it has been demonstrated a high incidence of insulin resistance in PCOS patients, our study aimed to evaluate the efficacy of the integrative treatment with D-chiro-inositol (DCI) (500 mg die, per os, for 12 weeks) on hormonal parameters and insulin sensitivity in a group of overweight/obese PCOS patients (body mass index; BMI > 26). After the treatment, interval several endocrine parameters improved (luteinizing hormone [LH], LH/follicle stimulating hormone [FSH], androstenedione and insulin), insulin response to oral glucose tolerance test reported the significant improvement of insulin sensitivity as well as the gonadotropin-releasing hormone (GnRH)-induced (10 µg, in bolus) LH response. BMI decreased, though no lifestyle modification was requested. When data were analyzed according to the presence or absence of first-grade diabetic relatives, PCOS patients with diabetic relatives showed greater improvement after DCI administration. In conclusion DCI administration is effective in restoring better insulin sensitivity and an improved hormonal pattern in obese hyperinsulinemic PCOS patients, in particular, in hyperinsulinemic PCOS patients who have diabetic relatives.

摘要

多囊卵巢综合征(PCOS)是一种常见的内分泌疾病,通过排卵稀少、雄激素过多和卵巢多囊形态影响生育能力。由于已证明PCOS患者中胰岛素抵抗的发生率很高,我们的研究旨在评估给予D-手性肌醇(DCI)(每日500毫克,口服,共12周)对一组超重/肥胖PCOS患者(体重指数;BMI>26)的激素参数和胰岛素敏感性的综合治疗效果。治疗后,多个内分泌参数得到改善(促黄体生成素[LH]、LH/促卵泡生成素[FSH]、雄烯二酮和胰岛素),口服葡萄糖耐量试验的胰岛素反应显示胰岛素敏感性显著改善,以及促性腺激素释放激素(GnRH)诱导(10微克,静脉推注)的LH反应。尽管未要求改变生活方式,但BMI有所下降。当根据是否有一级糖尿病亲属分析数据时,有糖尿病亲属的PCOS患者在给予DCI后改善更大。总之,给予DCI对恢复肥胖高胰岛素血症PCOS患者,特别是有糖尿病亲属的高胰岛素血症PCOS患者更好的胰岛素敏感性和改善激素模式有效。

相似文献

1
Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.D-手性肌醇(DCI)对肥胖型多囊卵巢综合征患者促黄体生成素(LH)和胰岛素分泌的调节作用。
Gynecol Endocrinol. 2014 Jun;30(6):438-43. doi: 10.3109/09513590.2014.897321. Epub 2014 Mar 7.
2
Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.肥胖型多囊卵巢综合征患者肌醇给药的胰岛素反应差异。
Gynecol Endocrinol. 2012 Dec;28(12):969-73. doi: 10.3109/09513590.2012.685205. Epub 2012 May 21.
3
Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.多囊卵巢综合征患者肌醇和 D-手性肌醇对卵巢功能和代谢因素影响的比较。
Gynecol Endocrinol. 2014 Mar;30(3):205-8. doi: 10.3109/09513590.2013.860120. Epub 2013 Dec 19.
4
Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.超重/肥胖多囊卵巢综合征患者接受肌醇(MYO)、硫辛酸(ALA)或两者联合治疗后,口服葡萄糖耐量试验(OGTT)的胰岛素反应差异。
Gynecol Endocrinol. 2019 Dec;35(12):1088-1093. doi: 10.1080/09513590.2019.1640200. Epub 2019 Jul 13.
5
Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome.肌醇调节正常体重多囊卵巢综合征患者的胰岛素和促黄体生成素分泌。
J Obstet Gynaecol Res. 2014 May;40(5):1353-60. doi: 10.1111/jog.12319. Epub 2014 Mar 9.
6
The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.40:1 肌醇/D-手性肌醇血浆比值能够恢复多囊卵巢综合征患者的排卵:与其他比值的比较。
Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5512-5521. doi: 10.26355/eurrev_201906_18223.
7
Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.吡格列酮对多囊卵巢综合征正常胰岛素水平和高胰岛素血症肥胖患者胰岛素及雄激素异常的选择性作用
Hum Reprod. 2003 Jun;18(6):1210-8. doi: 10.1093/humrep/deg264.
8
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.低热量饮食联合二甲双胍长期治疗对患有和未患有多囊卵巢综合征的腹型肥胖女性身体成分、脂肪分布、雄激素及胰岛素水平的影响
J Clin Endocrinol Metab. 2000 Aug;85(8):2767-74. doi: 10.1210/jcem.85.8.6738.
9
[Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].肥胖型多囊卵巢综合征肥胖女性的临床特征、激素谱及代谢异常
Zhonghua Yi Xue Za Zhi. 2005 Dec 7;85(46):3266-71.
10
The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.40:1 配比的肌醇和 D-手性肌醇对按照 Rotterdam 标准分类为表型 A 及按照 EGOI 标准分类为 EMS 类型 1 的多囊卵巢综合征女性的激素和代谢特征的影响。
Gynecol Obstet Invest. 2024;89(2):131-139. doi: 10.1159/000536163. Epub 2024 Jan 31.

引用本文的文献

1
Does MYO and ALA Supplementation Improve PCOS Outcomes?补充肌醇(MYO)和α-硫辛酸(ALA)能否改善多囊卵巢综合征(PCOS)的治疗效果?
Medicina (Kaunas). 2025 May 13;61(5):885. doi: 10.3390/medicina61050885.
2
PCOS and Inositols - Advances and Lessons We are Learning. A Narrative Review.多囊卵巢综合征与肌醇——我们正在汲取的进展与经验。一篇叙述性综述。
Drug Des Devel Ther. 2025 May 21;19:4183-4199. doi: 10.2147/DDDT.S524718. eCollection 2025.
3
Unexpected effects of treating insulin-resistant obese women with high-dose D-chiro-inositol: opening Pandora's box.
用高剂量D-手性肌醇治疗胰岛素抵抗肥胖女性的意外效果:打开潘多拉魔盒。
Front Endocrinol (Lausanne). 2025 Apr 1;16:1399308. doi: 10.3389/fendo.2025.1399308. eCollection 2025.
4
Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial.多囊卵巢综合征不同表型中肌醇与D-手性肌醇联合使用对比二甲双胍的疗效:一项前瞻性临床试验中对卵巢功能、排卵及应激反应的改善作用
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 23. doi: 10.1007/s00210-025-03813-9.
5
D-Chiro Inositol Supplementation and the Occurrence of Gestational Diabetes: A Randomized Controlled Trial in China.补充D-手性肌醇与妊娠期糖尿病的发生:一项中国的随机对照试验
Food Sci Nutr. 2024 Dec 5;13(1):e4601. doi: 10.1002/fsn3.4601. eCollection 2025 Jan.
6
Myo-Inositol and D-Chiro-Inositol Reduce DHT-Stimulated Changes in the Steroidogenic Activity of Adult Granulosa Cell Tumors.肌醇和 D-手性肌醇可降低 DHT 刺激的成年颗粒细胞瘤类固醇生成活性的改变。
Int J Mol Sci. 2024 Oct 12;25(20):10974. doi: 10.3390/ijms252010974.
7
<sc>d</sc>-Chiro-Inositol in Clinical Practice: A Perspective from the Experts Group on Inositol in Basic and Clinical Research (EGOI).《临床实践中的 D-手性肌醇:基础与临床研究手性肌醇专家组(EGOI)的观点》。
Gynecol Obstet Invest. 2024;89(4):284-294. doi: 10.1159/000536081. Epub 2024 Feb 19.
8
Myoinositols Prevent Gestational Diabetes Mellitus and Related Complications: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.肌醇预防妊娠糖尿病及其相关并发症:随机对照试验的系统评价和荟萃分析。
Nutrients. 2023 Sep 30;15(19):4224. doi: 10.3390/nu15194224.
9
Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance.多囊卵巢综合征作为代谢性疾病:关于胰岛素抵抗的新见解
touchREV Endocrinol. 2023 May;19(1):71-77. doi: 10.17925/EE.2023.19.1.71. Epub 2023 May 17.
10
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics.多囊卵巢综合征:病因、当前治疗及未来疗法
J Clin Med. 2023 Feb 11;12(4):1454. doi: 10.3390/jcm12041454.